Solventum Corporation (NYSE:SOLV) Receives Consensus Rating of “Hold” from Analysts

Solventum Corporation (NYSE:SOLV) has received an average recommendation of “Hold” from the thirteen brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $87.00.

A number of equities research analysts have recently issued reports on the stock. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Finally, BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Tuesday, December 2nd.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently modified their holdings of SOLV. Measured Wealth Private Client Group LLC bought a new position in shares of Solventum during the third quarter valued at approximately $25,000. CYBER HORNET ETFs LLC acquired a new position in Solventum during the 2nd quarter valued at approximately $28,000. Deseret Mutual Benefit Administrators increased its position in Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares during the period. Barrett & Company Inc. lifted its stake in Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after buying an additional 268 shares during the last quarter. Finally, MUFG Securities EMEA plc acquired a new position in shares of Solventum during the second quarter valued at $31,000.

Solventum Stock Performance

Solventum stock opened at $80.18 on Friday. Solventum has a 52 week low of $60.70 and a 52 week high of $88.20. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. The stock has a market cap of $13.91 billion, a P/E ratio of 9.24, a price-to-earnings-growth ratio of 8.46 and a beta of 0.26. The stock has a 50 day moving average of $77.56 and a 200-day moving average of $74.83.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the prior year, the company posted $1.64 earnings per share. The firm’s quarterly revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

Solventum announced that its Board of Directors has authorized a share buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 7.5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.